Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year

Cipla reports consolidated PAT of Rs. 675.80 Cr

Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025

Laurus Labs reports consolidated Q3 net profit of Rs. 251.66 Cr

Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025

Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.

Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM

The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo

GSK reports breakthrough results in chronic hepatitis B trials

Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer

The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2

Alumis reports breakthrough Phase 3 results for oral psoriasis therapy

The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data

PHARMEXCIL holds high-level talks with government to boost India’s pharma exports

India’s pharmaceutical sector stands at a pivotal inflection point